You are here:Home-Research Areas-Other Indications-Ulcer

Request The Product List ofUlcer Ulcer

Cat. No. Product Name CAS No. Information
PC-62591

GLPG 0974

1391076-61-1

GLPG 0974 is a potent, selective free fatty acid receptor 2 (FFA2, GPR43) antagonist with IC50 of 95 nM; inhibits acetate-induced neutrophil migration strongly in vitro with IC50 of 27 nM; demonstrates ability to inhibit a neutrophil-based pharmacodynamic (PD) marker, CD11b activation-specific epitope [AE], in a human whole blood assay.

Ulcer

Phase 2 Clinical

PC-42335

UK-371804

256477-09-5

UK-371804 is a potent and selective inhibitor of urokinase-type plasminogen activator (uPA) with Ki of 10 nM; displays excellent selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin); inhibits exogenous uPA in human chronic wound fluid with IC50 of 0.89 uM; penetrates into pig wounds and inhibits exogenous uPA activity with no adverse effect on wound healing parameters in wound model following topical delivery.

Ulcer

Preclinical

PC-62893

CS-526

313272-12-7 CS-526 (AKU 517;R 105266) is a potent, competitive, and reversible acid pump antagonist (potassium-competitive acid blocker) that inhibits H+,K+-ATPase activity with IC50 of 61 nM; inhibits gastric acid secretion in pylorus-ligated rats with ID50 of 0.7 mg/kg (p.o.); inhibits histamine-stimulated gastric acid secretion in Heidenhain pouch dogs, inhibits acute gastric mucosal lesions and has potent antisecretory and antiulcer effects.

Ulcer

Phase 1 Discontinued

PC-62892

Revaprazan

199463-33-7 Revaprazan (SB-641257;YH-1885) is a potent potassium-competitive acid blocker (P-CAB) that inhibits H+,K+-ATPase in a reversible and K+-competitive manner; reduces gastric acid secretion, also exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling.

Ulcer

Approved

PC-62891

Revaprazan hydrochloride

178307-42-1 Revaprazan (SB-641257;YH-1885) potent potassium-competitive acid blocker (P-CAB) that inhibits H+,K+-ATPase in a reversible and K+-competitive manner; reduces gastric acid secretion, also exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling.

Ulcer

Approved

PC-60826

TAK-438

1260141-27-2 A novel potent, potassium-competitive acid blocker (P-CAB) that inhibits H(+),K(+)-ATPase activity in porcine gastric microsomes with IC50 of 19 nM at pH 6.5; the inhibitory activity of TAK-438 is unaffected by ambient pH, but not SCH28080 and lansoprazole; completely inhibits basal and 2-deoxy-d-glucose-stimulated gastric acid secretion in rats at 4 mg/kg (as the free base) orally; a more potent and longer-lasting inhibitory action on gastric acid secretion than either lansoprazole or SCH28080.

Ulcer

Approved

PC-60811

Tegoprazan

942195-55-3 A novel potent, highly selective, competitive and orally active inhibitor of gastric H+/K+-ATPase with IC50 of ranging 0.29-0.52 uM porcine, canine and human H+/K+-ATPases in vitro; displays no activity against canine kidney Na+/K+-ATPase (IC50>100 uM); potently inhibits histamine-induced gastric acid secretion in dogs and a complete inhibition at 1.0 mg/kg starting from 1 hr after administration, reverses the pentagastrin-induced acidified gastric pH to the neutral range at 1-3 mg/kg, immediately evoks a gastric phase III contraction of migrating motor complex (MMC) in pentagastrin-treated dogs.

Ulcer

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com